Volume : 09, Issue : 12, December – 2022
Title:
104.STUDY ON IN VITRO CHOLESTEROL ESTERASE INHIBITORY ACTIVITY OF DELONIX ELATA LEAF EXTRACT
Authors :
S. K Godasu, D. Varun, G. Anusha, Nimma. Vijayarekha, Praveen Gujjula
Abstract :
This study was to evaluate the in vitro cholesterol esterase inhibitory activity of Delonix elata leaf extract. Phytochemical screening of powdered leaves of Delonix elata showed the presence of alkaloids, flavonoids, saponins, tannins, sterols, oil and fat, phenolic compound, protein and amino acid, gums and mucilages, carbo- hydrates, and glycosides. For the extract of DELE IC50 value was calculated and was found to be 46.66±11.66µg/ml. Gallic acid is used as a reference standard and IC50 value was found to be 45.66±10.039µg/ml. Saponins are also reported to precipitate cholesterol from micelles and interfere with enterohepatic circulation of bile acids making it unavailable for intestinal absorption, this forces liver to produce more bile from cholesterol and hence the reduction in serum cholesterol level. Saponins are also reported to lower triglycerides by inhibiting pancreatic lipoprotein lipase. Similarly in our study also, the presence of both flavanoids and saponins in DELE could have contributed in reducing the levels of lipid status (TC, TG,) elevated levels of serum low density lipoprotein cholesterol (LDL) and very low-density lipoprotein cholesterol (VLDL) are often accompanied by premature atherosclerosis and other CVD. A low level of high-density lipoprotein cholesterol (HDL) is also an important risk factor for cardiovascular disease.
Keywords: In Vitro, Cholesterol Esterase Inhibitory Activity, Delonix Elata, Leaf Extract
tegrants, Terfenadine, Crosspovidone, Sodium carboxy methyl cellulose. Direct Compression.
Cite This Article:
Please cite this article in press G. Suresh kumar et al, Study On In Vitro Cholesterol Esterase Inhibitory Activity Of Delonix Elata Leaf Extract .,Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
1. Flora GD, Nayak MK. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des. 2019;25(38):4063-84. doi: 10.2174/1381612825666190925163827, PMID 31553287.
2. Markus H. Stroke: Causes and clinical features. Medicine. 2016;44(9):515-20. doi: 10.1016/j.mpmed.2016.06.006.
3. Kaneko H, Itoh H, Kiriyama H, Kamon T, Fujiu K, Morita K, et al. Possible association between eating behaviors and cardiovascular disease in the general population: Analysis of a nationwide epidemiological database. Atherosclerosis. 2021;320:79-85. doi: 10.1016/j.atherosclerosis.2021.01.022, PMID 33581389.
4. Stephan Y, Sutin AR, Wurm S, Terracciano A. Subjective aging and incident cardiovascular disease. J Gerontol B Psychol Sci Soc Sci. 2021;76(5):910-9. doi: 10.1093/geronb/gbaa106, PMID 32857131.
5. Zhang H, Zeng Y, Yang H, Hu Y, Hu Y, Chen W, et al. Familial factors, diet, and risk of cardiovascular disease: A cohort analysis of the UK Biobank. Am J Clin Nutr. 2021;114(5):1837-46. doi: 10.1093/ajcn/nqab261, PMID 34375391.
6. Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225-45. doi: 10.1038/s41580-019-0190-7, PMID 31848472.
7. Horodinschi RN, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with statins in elderly patients. Medicina (Kaunas). 2019;55(11). doi: 10.3390/medicina55110721, PMID 31671689.
8. Feingold KR. Triglyceride lowering drugs. Endotext; 2020.
9. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017;2017(7). doi: 10.1002/14651858.CD006401.pub4.
10. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterollowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98(1):69-72. doi: 10.1093/jnci/djj006, PMID 16391373.
11. Rajurkar NS, Damame MM. Elemental analysis of some herbal plants used in the treatment of cardiovascular diseases by NAA and AAS. J Radioanal Nucl Chem. 1997;219(1):77-80. doi: 10.1007/BF02040269.
12. Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian J Physiol Pharmacol. 2005;49(2):125-31. PMID 16170979.
13. Kim JS, Ju JB, Choi CW, Kim SC. Hypoglycemic and antihyperlipidemic effect of four Korean medicinal plants in alloxan induced diabetic rats. Am J Biochem Biotechnol. 2006;2(4):154-60. doi: 10.3844/ajbbsp.2006.154.160.
14. Rouhi-Boroujeni H, Heidarian E, Rouhi-Boroujeni H, Deris F, Rafieian-Kopaei M. Medicinal plants with multiple effects on cardiovascular diseases: A systematic review. Curr Pharm Des. 2017;23(7):999-1015. doi: 10.2174/1381612822666161 021160524, PMID 27774898.
15. Shaito A, Thuan DTB, Phu HT, Nguyen THD, Hasan H, Halabi S, et al. Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety. Front Pharmacol. 2020;11:422. doi: 10.3389/fphar.2020.00422, PMID 32317975.
16. Wijayasiriwardena C, Sharma PP, Chauhan MG, Pillai APG. Delonix elata (L.) Gamble from folklore practice. Ayurvedic Pharmacopoeia of India. 2009;30:68–72. [Google Scholar]
17. Pavithra PS, Janani VS, Charumathi KH, Indumathy R, Potala S, Verma RS. Antibacterial activity of plants used in Indian herbal medicine. International Journal of Green Pharmacy. 2010;4(1):22–28. [Google Scholar]
18. Pradeepa K, Krishna V, Harish BG, Venkatesh, Kumar SSR, Kumar GK. Antibacterial activity of leaf extract of Delonix elata and molecular docking studies of Luteolin. Journal of Biochemical Technology. 2013;3:S198–S203. [Google Scholar]
19. Pradeepa K, Krishna V, Girish KK, Kumar S, Sr., Hoskeri JH, Gnanesh AU. Antinociceptive activity of Delonix elata leaf extract. Asian Pacific Journal of Tropical Biomedicine. 2012;2(1):S229–S231. [Google Scholar]
20.Sethuraman MG, Sulochana N. The anti-inflammatory activity of Delonix elata . Current Science. 1986; 55:343–344. [Google Scholar]